Title |
Prospective Surveillance for Cardiac Adverse Events in Healthy Adults Receiving Modified Vaccinia Ankara Vaccines: A Systematic Review
|
---|---|
Published in |
PLOS ONE, January 2013
|
DOI | 10.1371/journal.pone.0054407 |
Pubmed ID | |
Authors |
Marnie L. Elizaga, Sandhya Vasan, Mary A. Marovich, Alicia H. Sato, Dale N. Lawrence, Bernard R. Chaitman, Sharon E. Frey, Michael C. Keefer |
Abstract |
Vaccinia-associated myo/pericarditis was observed during the US smallpox vaccination (DryVax) campaign initiated in 2002. A highly-attenuated vaccinia strain, modified vaccinia Ankara (MVA) has been evaluated in clinical trials as a safer alternative to DryVax and as a vector for recombinant vaccines. Due to the lack of prospectively collected cardiac safety data, the US Food and Drug Administration required cardiac screening and surveillance in all clinical trials of MVA since 2004. Here, we report cardiac safety surveillance from 6 phase I trials of MVA vaccines. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 2% |
United States | 1 | 2% |
Unknown | 39 | 95% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 7 | 17% |
Student > Ph. D. Student | 5 | 12% |
Student > Bachelor | 4 | 10% |
Student > Master | 4 | 10% |
Student > Doctoral Student | 2 | 5% |
Other | 6 | 15% |
Unknown | 13 | 32% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 17 | 41% |
Nursing and Health Professions | 3 | 7% |
Immunology and Microbiology | 3 | 7% |
Agricultural and Biological Sciences | 2 | 5% |
Arts and Humanities | 1 | 2% |
Other | 2 | 5% |
Unknown | 13 | 32% |